case reports aspiration glp-1 receptor agonist anesthesia 2023 Perioperative management of agonists: a systematic review of potential risks | Perioperative Medicine GLP-1 agonists: a new hope

We started follow-up on the day after cohort entry and continued until outcome occurrence or until any of the following occurred: treatment discontinuation or starting a drug in the comparator class, death, end of continuous health plan enrollment, or end of available data

[DOI] [PubMed] [Google Scholar] 118.Baartscheer A., Schumacher C.A., Wst R.C.I., Fiolet J.W.T., Stienen G.J.M., Coronel R., Zuurbier C.J

95% CI [0.690.90])

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises